ZA200804301B - 1,5-substituted indol-2-yl amide derivatives - Google Patents
1,5-substituted indol-2-yl amide derivativesInfo
- Publication number
- ZA200804301B ZA200804301B ZA200804301A ZA200804301A ZA200804301B ZA 200804301 B ZA200804301 B ZA 200804301B ZA 200804301 A ZA200804301 A ZA 200804301A ZA 200804301 A ZA200804301 A ZA 200804301A ZA 200804301 B ZA200804301 B ZA 200804301B
- Authority
- ZA
- South Africa
- Prior art keywords
- amide derivatives
- substituted indol
- indol
- substituted
- amide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05111478 | 2005-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200804301B true ZA200804301B (en) | 2009-04-29 |
Family
ID=37814240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200804301A ZA200804301B (en) | 2005-11-30 | 2008-05-19 | 1,5-substituted indol-2-yl amide derivatives |
Country Status (18)
Country | Link |
---|---|
US (1) | US7745479B2 (fr) |
EP (1) | EP1957479B1 (fr) |
JP (1) | JP4879997B2 (fr) |
KR (1) | KR101124156B1 (fr) |
CN (1) | CN101316840B (fr) |
AR (1) | AR057989A1 (fr) |
AT (1) | ATE500244T1 (fr) |
AU (1) | AU2006319234B2 (fr) |
BR (1) | BRPI0619268A2 (fr) |
CA (1) | CA2630314A1 (fr) |
DE (1) | DE602006020482D1 (fr) |
ES (1) | ES2359739T3 (fr) |
IL (1) | IL191314A (fr) |
NO (1) | NO20082136L (fr) |
RU (1) | RU2008126391A (fr) |
TW (1) | TWI333490B (fr) |
WO (1) | WO2007062999A2 (fr) |
ZA (1) | ZA200804301B (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE466007T1 (de) * | 2005-11-30 | 2010-05-15 | Hoffmann La Roche | 5-substituierte indol-2-carbonsäureamidderivate |
ES2362929T3 (es) * | 2005-11-30 | 2011-07-15 | F. Hoffmann-La Roche Ag | Derivados de 1,1-dioxo-tiomorfolinil-indolil-metanona para uso como moduladores de h3. |
TW200823204A (en) * | 2006-10-17 | 2008-06-01 | Arena Pharm Inc | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto |
WO2008083124A1 (fr) | 2006-12-28 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Composés d'hétérocycloalkyloxybenzamide n-substitués, et procédés d'utilisation |
US7507736B2 (en) * | 2007-02-07 | 2009-03-24 | Hoffmann-La Roche Inc. | Indol-2-yl-piperazin-1-yl-methanone derivatives |
WO2009065131A1 (fr) * | 2007-11-16 | 2009-05-22 | Rigel Pharmaceuticals, Inc. | Composés de carboxamide, de sulfonamide et d'amine pour des troubles métaboliques |
US8129390B2 (en) * | 2007-12-12 | 2012-03-06 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds and methods for using the same |
ES2552549T3 (es) | 2008-04-23 | 2015-11-30 | Rigel Pharmaceuticals, Inc. | Compuestos de carboxamida para el tratamiento de trastornos metabólicos |
US8765737B1 (en) * | 2010-05-11 | 2014-07-01 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
US9394294B2 (en) * | 2010-05-11 | 2016-07-19 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
US8741891B1 (en) | 2010-06-22 | 2014-06-03 | Demerx, Inc. | N-substituted noribogaine prodrugs |
US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
MX2013000733A (es) | 2010-07-23 | 2013-05-30 | Demerx Inc | Composiciones de noribogaina. |
EP2481740B1 (fr) | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Procédés et compositions pour préparer de la noribogaïne à partir de voacangine |
US9617274B1 (en) | 2011-08-26 | 2017-04-11 | Demerx, Inc. | Synthetic noribogaine |
CN103842356B (zh) | 2011-10-07 | 2017-03-15 | 武田药品工业株式会社 | 用于治疗神经变性疾病的1‑芳基羰基‑4‑氧‑哌啶化合物 |
CA2855994A1 (fr) | 2011-12-09 | 2013-06-13 | Demerx, Inc. | Esters phosphoriques de noribogaine |
WO2013112673A1 (fr) | 2012-01-25 | 2013-08-01 | Demerx, Inc. | Voacangine synthétique |
US8940728B2 (en) | 2012-12-20 | 2015-01-27 | Demerx, Inc. | Substituted noribogaine |
WO2014098877A1 (fr) | 2012-12-20 | 2014-06-26 | Demerx, Inc. | Noribogaïne substituée |
US9045481B2 (en) | 2012-12-20 | 2015-06-02 | Demerx, Inc. | Substituted noribogaine |
US9422281B2 (en) | 2013-11-18 | 2016-08-23 | Forma Therapeutics, Inc. | Benzopiperazine compositions as BET bromodomain inhibitors |
HUE053645T2 (hu) | 2013-11-18 | 2021-07-28 | Forma Therapeutics Inc | Tetrahidrokinolin kompozíciók mint BET bromodomén inhibitorok |
CN105523986A (zh) * | 2015-12-30 | 2016-04-27 | 江汉大学 | 一种外排泵抑制剂n-氢-2-芳基吲哚及其衍生物的合成方法 |
CN115340460A (zh) * | 2022-09-21 | 2022-11-15 | 江西亚太科技发展有限公司 | 一种Reissert吲哚合成反应中间体的合成方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1247547A (fr) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Derives de leucine |
US5246960A (en) | 1984-12-21 | 1993-09-21 | Hoffmann-La Roche Inc. | Oxetanones |
CA1270837A (fr) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
CA1328881C (fr) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Procede pour la fabrication d'oxetanones |
CA2035972C (fr) | 1990-02-23 | 2006-07-11 | Martin Karpf | Procede de preparation d'oxetanones |
US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
CA2340056C (fr) | 1998-08-14 | 2007-01-09 | F. Hoffmann-La Roche Ag | Compositions pharmaceutiques comportant des inhibiteurs de lipase |
EP1105123B1 (fr) | 1998-08-14 | 2004-04-07 | F.Hoffmann-La Roche Ag | Compositions pharmaceutiques contenant des inhibiteurs de lipases et du chitosane |
ATE278680T1 (de) | 1999-03-29 | 2004-10-15 | Hoffmann La Roche | Glukokinase aktivatoren |
GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
US20060052597A1 (en) * | 2002-10-22 | 2006-03-09 | Best Desmond J | Aryloxyalkylamine derivatives as h3 receptor ligands |
ES2306170T3 (es) * | 2004-06-21 | 2008-11-01 | F. Hoffmann-La Roche Ag | Derivados de indol como antagonistas redeptores de histamina. |
ES2362929T3 (es) * | 2005-11-30 | 2011-07-15 | F. Hoffmann-La Roche Ag | Derivados de 1,1-dioxo-tiomorfolinil-indolil-metanona para uso como moduladores de h3. |
US7507736B2 (en) * | 2007-02-07 | 2009-03-24 | Hoffmann-La Roche Inc. | Indol-2-yl-piperazin-1-yl-methanone derivatives |
-
2006
- 2006-11-20 KR KR1020087015768A patent/KR101124156B1/ko not_active IP Right Cessation
- 2006-11-20 DE DE602006020482T patent/DE602006020482D1/de active Active
- 2006-11-20 CN CN2006800448399A patent/CN101316840B/zh not_active Expired - Fee Related
- 2006-11-20 RU RU2008126391/04A patent/RU2008126391A/ru unknown
- 2006-11-20 CA CA002630314A patent/CA2630314A1/fr not_active Abandoned
- 2006-11-20 WO PCT/EP2006/068655 patent/WO2007062999A2/fr active Application Filing
- 2006-11-20 AT AT06830046T patent/ATE500244T1/de active
- 2006-11-20 JP JP2008542716A patent/JP4879997B2/ja not_active Expired - Fee Related
- 2006-11-20 AU AU2006319234A patent/AU2006319234B2/en not_active Ceased
- 2006-11-20 BR BRPI0619268-8A patent/BRPI0619268A2/pt not_active IP Right Cessation
- 2006-11-20 EP EP06830046A patent/EP1957479B1/fr not_active Not-in-force
- 2006-11-20 ES ES06830046T patent/ES2359739T3/es active Active
- 2006-11-27 US US11/604,412 patent/US7745479B2/en not_active Expired - Fee Related
- 2006-11-28 TW TW095144012A patent/TWI333490B/zh not_active IP Right Cessation
- 2006-11-28 AR ARP060105248A patent/AR057989A1/es not_active Application Discontinuation
-
2008
- 2008-05-07 NO NO20082136A patent/NO20082136L/no not_active Application Discontinuation
- 2008-05-07 IL IL191314A patent/IL191314A/en not_active IP Right Cessation
- 2008-05-19 ZA ZA200804301A patent/ZA200804301B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP4879997B2 (ja) | 2012-02-22 |
RU2008126391A (ru) | 2010-01-10 |
WO2007062999A2 (fr) | 2007-06-07 |
WO2007062999A3 (fr) | 2007-07-26 |
AR057989A1 (es) | 2008-01-09 |
DE602006020482D1 (de) | 2011-04-14 |
EP1957479B1 (fr) | 2011-03-02 |
AU2006319234A1 (en) | 2007-06-07 |
NO20082136L (no) | 2008-06-30 |
TWI333490B (en) | 2010-11-21 |
IL191314A (en) | 2012-06-28 |
KR101124156B1 (ko) | 2012-03-23 |
TW200804340A (en) | 2008-01-16 |
CA2630314A1 (fr) | 2007-06-07 |
US20070123515A1 (en) | 2007-05-31 |
JP2009517433A (ja) | 2009-04-30 |
ATE500244T1 (de) | 2011-03-15 |
US7745479B2 (en) | 2010-06-29 |
CN101316840A (zh) | 2008-12-03 |
ES2359739T3 (es) | 2011-05-26 |
CN101316840B (zh) | 2012-08-08 |
EP1957479A2 (fr) | 2008-08-20 |
BRPI0619268A2 (pt) | 2011-09-20 |
KR20080076980A (ko) | 2008-08-20 |
AU2006319234B2 (en) | 2012-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200804301B (en) | 1,5-substituted indol-2-yl amide derivatives | |
ZA200606974B (en) | Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives | |
GB0504019D0 (en) | Amide derivatives | |
IL211894A0 (en) | Amide derivatives | |
IL183657A0 (en) | Amide derivatives | |
EP1830858A4 (fr) | 3,6-bicyclolides | |
ZA200800920B (en) | Amide derivatives | |
TWI315670B (en) | Substituted aryl 1,4-pyrazine derivatives | |
GB0507114D0 (en) | No 1 timemachine | |
IL184677A0 (en) | Substituted 1,1,1-trifluoro-3-[(benzyl)- | |
IL182538A0 (en) | 1,5-diheterocycle-1h-triazole derivative | |
GB0425572D0 (en) | 1,7-Naphthyridines | |
GB0509703D0 (en) | Hayfit 2 | |
IL188111A0 (en) | 2,5-bis-diamimne [1,4] benzoquinone-derivatives | |
EP1711189A4 (fr) | Derives d'azalide 8a 6,11-3c-bicyclique | |
IL186226A0 (en) | (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines | |
GB0514559D0 (en) | Qmaster 2005 | |
EP1940415A4 (fr) | 19,23,24,25,26,27-hexanor-1alpha-hydroxyvitamine d3 | |
ZA200705150B (en) | Amide derivatives | |
GB0507513D0 (en) | Amide derivatives | |
GB0526315D0 (en) | Amide derivatives | |
GB0409800D0 (en) | Amide derivatives | |
GB0409804D0 (en) | Amide derivatives | |
GB0514110D0 (en) | iCorcost 8 | |
GB0517452D0 (en) | iCorcost 5 |